Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery

Share on Stocktwits


The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.'

Imagin Medical Inc. (IME:CSE; IMEXF:OTCQB) is developing technology that can greatly improve the ability to visualize cancer during minimally invasive surgeries. Its i/Blue Imaging™ System is in development for use in bladder cancer, the sixth most common cancer in the United States. The company has just hit the significant milestone of completing design verification for the system.

The company and its technology have caught the attention of two industry observers.

Chris Temple, editor and publisher of The National Investor, writes that Imagin Medical's "disruptive technology is poised to deliver the most significant advancement in bladder cancer detection and removal in decades, making the detection and removal of cancer FAR more efficient and effective."

"Imagin's i/Blue Imaging System has the potential to be a game-changer." - Chris Temple

Concerning the value proposition, Temple writes, "There certainly does appear to be a great potential reward here to go with the usual risk. As of this writing, Imagin has a market cap of a tiny C$7 million, or about US$ 5.4 million. Compare that against—first—the US$4 billion market on bladder cancer scoping alone, not to mention that—if successful here—Imagin may well be poised to proceed to disrupt other segments of the endoscopy market."

Imagin's technology has the support of experts in the field. "Already, Imagin's i/Blue Imaging System is being embraced by urologists; most recently at the American Urological Association's annual meeting, held in May in Chicago. Imagin held private focus groups, where leading urologists assessed the initial functional product and provided overwhelmingly positive feedback that was used to finalize the i/Blue product user's needs," Temple writes.

"So compelling is Imagin's proprietary technology and potential benefits for both medical professionals and especially patients that leading urologists have even invested in Imagin Medical," he states.

Imagine Medical's "technology holds the promise of leading to the most efficient detection and removal of bladder cancer of anything the industry has seen in some 30 years. Managed by a team with past success already in bringing transformative new products to market, Imagin has already been embraced by key urologists and opinion leaders in that industry. Some of them have already become shareholders of Imagin Medical to boot!" writes Temple.

"The need for a better, more efficient, modern standard of care is indisputable. Bladder cancer is the sixth-most prevalent cancer in America. One reason for its recurrence in too many patients is that the medical profession is, quite simply, using dated technology to detect bladder cancer in the first place. Imagin's i/Blue Imaging System has the potential to be a game-changer in this area," Temple concludes.

Read Chris Temple's article here in its entirety.

Technical analyst Clive Maund also follows Imagin Medical closely. Writing in on January 7, Maund stated, "We were accumulating Imagin Medical stock last fall, most recently in November, and the good news is that it has just staged a dramatic breakout, almost doubling in the last three trading days, or just since the start of the year.

"We can see this dramatic breakout to advantage on the latest 3-month chart, with it soaring above its 200-day moving average on expanding volume to become quite heavily overbought on a short-term basis, which makes it tempting to take profits or at least scale back positions, but should we?"

The longer-term charts come in most useful with respect to making such a decision. The 4-year chart shows that when this stock decides to go up, it goes up big, as it did most notably in late 2017 and early 2018. The spike moves can continue for a long time until it becomes massively overbought, and given that this company has a great invention, as we have already observed, it might be foolishly premature to sell this here as it could go much higher. So we stay long and it is a buy on any dips that might occur.


1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Imagin Medical. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Imagin Medical. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of Imagin Medical. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Imagin Medical, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Additional disclosures
The National Investor has a financial relationship with the following companies mentioned in this article: Imagin Medical.
Clive Maund does not own shares of Imagin Medical and neither he nor his company has been paid by the company.

Want to read more about Life Sciences Tools & Diagnostics and Medical Devices investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe